iRGD in combination with IL-2 reprograms tumor immunosuppression.

Gregory P. Botta,Tatiana Hurtado de Mendoza,Harri Jarvelainen,Erkki Ruoslahti

iRGD in combination with IL-2 reprograms tumor immunosuppression.

2019

Gregory P. Botta
Tatiana Hurtado de Mendoza
Harri Jarvelainen
Erkki Ruoslahti

55Background: Fibrotic solid tumors have lagged in immunotherapy efficacy. Although breast cancer (BC) shows modest single-agent activity, pancreatic ductal adenocarcinoma (PDAC) immunotherapy has ...

Keywords:

Immunosuppression
Pathology
Medicine
Cancer research
Breast cancer
pancreatic ductal adenocarcinoma
Immunotherapy
tumor immunosuppression

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations